ENDRA Life Sciences (NDRA) Q2 2024 Earnings Report

861 Followers

Previous Report: Q1 2024

Next Report: Q3 2024

NDRA Q2 2024 EPS Results

Actual EPS-$140.00

Consensus EPS-$122.50

Beat/MissMissed by -$17.50

One Year Ago EPS-$752.50

NDRA Q2 2024 Revenue Results

Actual Revenue$0.00

Expected Revenue$0.00

Beat/MissMet expectations

YoY Revenue Growth―

Earnings Announcement Details

QuarterQ2 2024

Date08/22/2024

TimeAfter Close

Conference CallThursday, August 22, 2024

NDRA Upcoming Earnings

ENDRA Life Sciences's next earnings date is estimated for November 16, 2026, based on past reporting schedules.

Q2 2024 Earnings Call Audio

NDRA Q2 2024 Earnings Call

0:00 / 0:00

Q2 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2024 Earnings Call Summary

Q2 2024

Earnings Call Date:Aug 22, 2024|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call presented several strategic initiatives aimed at improving ENDRA's focus and operational efficiency, alongside positive developments in management, regulatory strategy, and intellectual property. However, financial challenges and stock performance issues remain concerns.

Company Guidance

During the ENDRA Life Sciences Q2 2024 earnings call, significant guidance was provided by the management team, outlining various strategic initiatives. Notably, the company has completed a 1-for-50 reverse stock split aimed at maintaining its NASDAQ listing, though recent high warrant exercise volumes have impacted their stock price adversely. Six key operational changes were introduced, including the enhancement of the management team with the addition of a seasoned CFO and a new Head of Clinical and Regulatory Affairs. The company plans to conduct a statistically-powered multicenter prospective clinical trial, expanding the number of subjects from 20 to 250. The financial update revealed a $7.3 million net raise from a public offering, with operating expenses reduced by 26% on an annual basis. ENDRA's goal is to complete clinical work and submit a de novo application to the FDA by mid-2025, with the current cash runway projected to fund the company into the first half of 2025. The management reiterated their confidence in ENDRA's technology and market potential, highlighting ongoing efforts to formalize a long-term business strategy and improve financial execution.

Enhanced Management Team

ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.

Strategic Regulatory Changes

The company is implementing a new FDA regulatory strategy, transitioning from retrospective data to a hypothesis-driven, statistically-powered prospective clinical trial, increasing the number of subjects from 20 to about 250 to achieve statistical power.

Significant Reduction in Operating Expenses

ENDRA reduced operating expenses by over $3 million, approximately a 26% reduction on an annualized basis, without impacting key deliverables, such as clinical data collection for FDA submission.

Strong Intellectual Property Portfolio

The patent portfolio now includes 81 issued patents globally, with 5 additional patents issued in Q2 2024, covering thermoacoustic technology and other applications.

Positive FDA Alignment

Positive feedback from an FDA meeting confirmed alignment on product configuration, clinical study design, and regulatory pathway, setting a clear path for the TAEUS liver device.

NDRA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 16, 2026	2026 (Q3)	-0.84 / -	-2.1	―
Aug 17, 2026	2026 (Q2)	-0.84 / 0.12	-1.71	107.08% (+1.83)
May 18, 2026	2026 (Q1)	- / -1.09	-1.86	41.40% (+0.77)
Mar 31, 2026	2025 (Q4)	-1.23 / -1.09	-1.86	41.40% (+0.77)
Nov 17, 2025	2025 (Q3)	-1.95 / -2.10	-9.54	77.99% (+7.44)
Jun 30, 2025	2025 (Q2)	-2.27 / -1.71	-140	98.78% (+138.29)
May 15, 2025	2025 (Q1)	- / -1.86	-455	99.59% (+453.14)
Mar 31, 2025	2024 (Q4)	-3.91 / -1.86	-455	99.59% (+453.14)
Nov 15, 2024	2024 (Q3)	-62.30 / -9.54	-700	98.64% (+690.46)
Aug 22, 2024	2024 (Q2)	-122.50 / -140.00	-752.5	81.40% (+612.50)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed